BioXcel Operating Cycle from 2010 to 2026
| BTAI Stock | USD 1.57 0.01 0.63% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 157.26 | Current Value 149.4 | Quarterly Volatility 15.8 K |
Check BioXcel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioXcel Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 18.3 M, Selling General Administrative of 27.2 M or Other Operating Expenses of 71.8 M, as well as many indicators such as Price To Sales Ratio of 7.31, Dividend Yield of 0.0 or Days Sales Outstanding of 23.05. BioXcel financial statements analysis is a perfect complement when working with BioXcel Therapeutics Valuation or Volatility modules.
BioXcel | Operating Cycle | Build AI portfolio with BioXcel Stock |
The Operating Cycle trend for BioXcel Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether BioXcel Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest BioXcel Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of BioXcel Therapeutics over the last few years. It is BioXcel Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioXcel Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
BioXcel Operating Cycle Regression Statistics
| Arithmetic Mean | 27,948 | |
| Geometric Mean | 10,827 | |
| Coefficient Of Variation | 56.65 | |
| Mean Deviation | 13,030 | |
| Median | 36,468 | |
| Standard Deviation | 15,832 | |
| Sample Variance | 250.6M | |
| Range | 36.3K | |
| R-Value | (0.74) | |
| Mean Square Error | 122.3M | |
| R-Squared | 0.54 | |
| Significance | 0.0007 | |
| Slope | (2,309) | |
| Total Sum of Squares | 4B |
BioXcel Operating Cycle History
About BioXcel Therapeutics Financial Statements
Investors use fundamental indicators, such as BioXcel Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Although BioXcel Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 157.26 | 149.40 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of BioXcel Therapeutics Correlation against competitors. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is there potential for Biotechnology market expansion? Will BioXcel introduce new products? Factors like these will boost the valuation of BioXcel Therapeutics. Projected growth potential of BioXcel fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.29) | Revenue Per Share | Quarterly Revenue Growth (0.54) | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioXcel Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioXcel Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioXcel Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.